Introduction
At birth, fluid present in the lung must be rapidly cleared to allow for the entry of air during the respiratory cycle. The amiloridesensitive epithelial sodium channel, ENaC, which is expressed at the apical surface of the airway epithelium, is thought to have a crucial role in the postnatal process of lung fluid absorption. 1, 2 In airway epithelium, ENaC is composed of three homologous subunits (a, b and g), which are coded for by the SCNN1A, SCNN1, and SCNN1C genes, respectively; assembly of functional active sodium channels is dependent on the a-subunit. Intratracheal instillation of amiloride, a specific inhibitor of the ENaC apical sodium channel, impairs lung water clearance in newborn guinea pigs. 3 Homozygous a-ENaC knockout mice show retention of fetal lung liquid and die of severe respiratory distress within 40 h after birth. 4 Thus, it has been hypothesized that ENaC has an important role in the pathogenesis of impaired respiratory adaptation after birth, especially transient tachypnea of the newborn, which occurs as a result of a delay in the clearance of fetal lung liquid.
Case
The patient is the first infant of second-degree cousins of Tunisian origin. Gestation was assured by early ultrasound. His mother had mild gestational diabetes, treated with diet. After premature rupture of membranes, she received antibiotics and a full course of betamethasone (2 Â 12 mg intramuscularly) for fetal lung maturation 2 days before delivery. The infant was subsequently born by spontaneous vaginal delivery at 33 weeks of gestation with a birth weight of 2280 g. He had an uneventful postnatal adaptation, his Apgar scores being 9, 9 and 9 at 1, 5, and 10 min, respectively, of life. No supplemental oxygen or any other respiratory support was required during his first days of life. A chest Y-ray taken at the second day of life showed well-aerated lungs with some streaky markings. He became symptomatic at the ninth day of life with hyperthermia, lethargy, low Na þ (126 mmol l À1 ), high K þ (8.9 mmol l À1 ), high aldosterone (>3000 ng l À1 ) and high renin (>1000 ng l À1 ) plasma concentrations, commensurate with pseudohypoaldosteronism (PHA) type I. Despite high Na þ load (45 mmol per kg body weight per day, administered by a gastrostomy tube), the boy kept having episodes of severe hyperkalemia, with serum K þ concentrations exceeding 12 mmol l
À1
). Repeatedly, there have been episodes of severe dehydration in the presence of viral diarrhea or airway infection. Auscultation has been dominated by wheezing with rhonchi and bilateral rales even in the absence of overt respiratory distress. Repeated radiographs showed opaque upper lung fields and hyperaerated lower lung fields. Inhaled corticosteroids, b2-mimetics, or N-acetyl cysteine were of no avail.
Sequencing of the SCNN1A gene (Dr Maria Christina Zennaro, INSERM U772, Paris, France) revealed a homozygous mutation (c.1678G>A), resulting in an exchange of glycine to serine in ENaC-a unit protein. The equivalent residue in the SCNN1A gene in the rat reduces the ENaC current by B80% (Dr Maria Christina Zennaro, personal communication), but the mutation has not been described in humans and has not been functionally tested, for example, in Xenopus laevis oocytes. Discussion PHA is a rare heterogeneous syndrome of mineralocorticoid resistance causing insufficient potassium and hydrogen secretion, characterized by neonatal salt loss, hyperkalemia, failure to thrive and dehydration. Although autosomal dominant PHA type 1 has been linked to mutations in the mineralocorticoid receptor-coding gene NR3C2, mutations in the ENaC subunit genes (SCNN1A, SCNN1B and SCNN1G) cause the more severe phenotype of autosomal recessive PHA type 1. 5 Autosomal recessive PHA1 is a life-long disease, and patients with inactivating SCNN1A, SCNN1B or SCNN1G mutations show no improvement over time, being prone to life-threatening salt-losing crises combined with severe hyperkalemia and dehydration.
Children with PHA type 1 based on mutations in genes coding for the a-or b-ENaC have an increased volume of liquid in the airways due to absorption failure 6 and present with recurrent pulmonary problems, such as wheezing, cough, tachypnea and lower respiratory tract infections. 7, 8 There are, however, no reports about respiratory distress immediately after birth in PHA patients born at term, 6 whereas one preterm infant (gestational age 31 weeks) with PHA had severe respiratory distress that was poorly responsive to surfactant replacement therapy. 9 Although the renal phenotype of this patient was very severe, some residual ENaC activity might be sufficient for postnatal lung water clearance, in conjunction with other sodium channels. 10, 11 The reduced ENaC activity may be enough to establish a normal air-liquid interface at birth while failing to prevent salt loss in the kidney. In the presence of a mutated a-chain, significant residual activity has indeed been found in vitro in channel pores consisting of only the b-and g-units.
12 Furthermore, ENaC expression is upregulated by corticosteroids, 13, 14 and the alveolar ENaC density of the infant at birth was presumably increased by the antenatal betamethasone medication. We assume that there are other mechanisms for fluid reabsorption in the lung at birth that compensate for the absence or insufficient expression of ENaC
The present case of a preterm infant of 33-week gestational age illustrates that a-ENaC may not be pivotal for the clearance of fetal lung liquid at this stage of maturation. The situation is quite different in mice: Although a-unit ENaCÀ/À mice die of respiratory insufficiency because of inability to clear their lungs of liquid, 4 b-unit ENaC knockout mice breathe normally at birth but develop severe PHA, succumbing at the second day of life to dehydration and hyperkalemia. 15 Thus, the clinical phenotype of a-ENaC deficiency in humans resembles more closely that of murine b-ENaC deficiency.
